INTRODUCTION
Purpose: The phosphatidylinositol 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway has a central role in regulation of cell proliferation, differentiation, motility and survival. This pathway has recently generated great interest because its elements are, potentially, novel targets for the treatment of various malignancies, including breast cancer. Methods: Using tissue microarray sections of breast carcinoma, we performed immunohistochemical studies using antibodies against the phosphorylated forms of Akt (p-Akt) and mTOR (p-mTOR) in 530 invasive breast carcinomas and 30 ductal carcinomas in situ (DCIS). We investigated possible associations between expression of these proteins and clinicopathologic characteristics and disease outcomes. Results: In 530 invasive carcinomas, weak and strong expression of p-Akt was observed in 180 (34.0%) and 288 (54.3%) cases, respectively. The expression of p-Akt was associated with expression of estrogen receptors (ER) (p =0.045), progesterone receptors (PR) (p =0.003), lymph node metastasis (p <0.001) and cancer stage (p =0.027). Weak and strong expression of p-mTOR was found in 136 (25.7%) and 207 (39.1%) cases, respectively. The mTOR pathway was more frequently activated in DCIS than in invasive breast carcinoma (p=0.001). p-mTOR expression was associated with expression of ER (p =0.040), PR (p=0.009), tumor size (p<0.001), and stage (p=0.002). In a univariate analysis, strong expression of p-Akt was associated with longer disease-free survival (DFS). In a multivariate analysis, neither p-Akt nor p-mTOR was associated with DFS. Conclusion: The PI3K/Akt/mTOR pathway is active in DCIS as well as in invasive carcinoma of the breast. Our study also suggests that the PI3K/Akt/mTOR pathway is influenced by ER rather than erbB-2, and that this pathway may contribute more to cancer pathogenesis in ER-positive tumors. was detected using a polymer secondary antibody from the DAKO EnVision+ system (DAKO, Carpinteria, USA).
METHODS

Tissue samples and clinicopathologic data
The slides were rinsed with a TBS series and visualized after a 10 min incubation of liquid 3, 3′ -diaminobenzidine in buffered substrate (DAKO, Carpinteria, USA) for 10 min.
The slides were counterstained with hematoxylin.
Assessment of immunohistochemical staining
We assessed immunohistochemical staining of TMA sections in a semiquantitative manner. Expression levels of p-Akt and p-mTOR were categorized into three groups based on both intensity and proportion of cancer cells with cytoplasmic or nuclear staining. This was done according to a previously described scoring system with a slight modification. (9) score and the intensity score were added to obtain a total score. Cases with a total score of 3 or more were considered positive.
With regard to erbB-2, a cancer cell with membranous staining was considered as an immunoreactive one, and was evaluated to determine a score. Membranous staining of erbB-2 was evaluated using the HercepTest � (DAKO, Carpinteria, USA) scoring method as follows: cores with more than 10% of strong membranous staining, 3; cores with more than 10% of moderate staining, 2; cores with more than 10% of weak staining, 1. erbB-2-positive cases were defined as those for which the score was 3.
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Western blot
To validate the specificity of the antibodies used in this 
Statistical analysis
RESULTS
Clinicopathologic characteristics
Of the 530 invasive carcinomas, most cases were ductal (497 cases, 93.8%). The distribution of 530 invasive carcinoma cases according to clinicopathologic characteristics at diagnosis is summarized in 
Frequency of p-Akt and p-mTOR expression
Using the criteria described above, weak and strong whereas it was 79.9% in p-Akt strong-positive tumors (p=0.004). This difference is shown in Figure 4 . Patients with large tumor size, metastasis in the lymph nodes and young age had decreased DFS. In contrast to p-Akt, pmTOR expression showed no statistical significance in DFS (p=0.136) ( Figure 5 ).
As shown in Table 6 , multivariate regression analysis using the Cox proportional hazards regression model, including p-Akt, p-mTOR, ER, PR, tumor grade, tumor size, status of lymph node metastasis and age, demonstrated the tumor size (hazard ratio, 1.730; p=0.009) and the status of lymph node metastasis (hazard ratio, 2.247; p<0.001) to be independent prognostic factors for DFS.
None of the other parameters that were studied showed a significant effect on DFS, although strong expression of p-Akt tended to be associated with longer DFS (p= 0.066).
DISCUSSION
The present study evaluated the expression of p-Akt and p-mTOR. We found a correlation between p-Akt and p-mTOR, indicating that Akt is a main up-regulator of the downstream target, mTOR, although there are complex regulatory pathways upstream of mTOR. p-Akt
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p-Akt=phosphorylated Akt; p-mTOR=phosphorylated mTOR; ER= estrogen receptor; PR=progesterone receptor; DFS=disease-free survival. *Tumors without reaction were scored as 0, tumors with 1-50% of cells with weak staining or 1-10% of cells with strong staining were scored as 1, and tumors with >50% of cells with weak staining or >10% of cells with strong staining were scored as 2. The results of this study showed that TOR is more fre- 
